Eddie Hickman
Stock Analyst at Guggenheim
(4.26)
# 423
Out of 5,116 analysts
19
Total ratings
66.67%
Success rate
16.48%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATAI AtaiBeckley | Initiates: Buy | $11 | $3.76 | +192.55% | 1 | Jan 20, 2026 | |
| PMN ProMIS Neurosciences | Maintains: Buy | $150 → $125 | $14.16 | +782.77% | 3 | Nov 18, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $84 → $87 | $64.54 | +34.80% | 9 | Nov 5, 2025 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.44 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $9.00 | +144.44% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $15.66 | +104.34% | 1 | Mar 13, 2025 |
AtaiBeckley
Jan 20, 2026
Initiates: Buy
Price Target: $11
Current: $3.76
Upside: +192.55%
ProMIS Neurosciences
Nov 18, 2025
Maintains: Buy
Price Target: $150 → $125
Current: $14.16
Upside: +782.77%
Tarsus Pharmaceuticals
Nov 5, 2025
Maintains: Buy
Price Target: $84 → $87
Current: $64.54
Upside: +34.80%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.44
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $9.00
Upside: +144.44%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $15.66
Upside: +104.34%